Neoantigen Cancer Vaccine Helps BioNTech Advance Oncology Ambitions

Encouraging 50% Response Rate

 
• By Andrew McConaghie
  
BioNTech
mRNA-based BNT122 is just one of BioNTech's novel immunotherapy modalities. • Source: BioNTech

More from ASCO

More from Conferences